Cephalexin

Product NDC: 68289-008
11-digit product format: 682890008
Labeler code: 68289
Product ID: 68289-008_24fc53ef-d9ef-401a-8bbe-3fc0d76a6cf8
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: Cephalexin
Dosage form: SUSPENSION
Route: ORAL
Labeler: Jazeera Pharmaceutical
Application: ANDA065444
Marketing category: ANDA
Marketing start: 2009-09-01
Marketing end: 0000-00-00
Substance: CEPHALEXIN ANHYDROUS
Active strength: 125 mg/5mL
Pharmacologic classes: Cephalosporin Antibacterial [EPC],Cephalosporins [CS]
NDC exclude flag: E
Listing certified through: 2017-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 3 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Source date
excluded product	product	68289-008		I	Inactivated by FDA	2026-08-03
excluded package	package	68289-008	68289-008-01	I	Inactivated by FDA	2026-08-03
excluded package	package	68289-008	68289-008-20	I	Inactivated by FDA	2026-08-03

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 2 · 66 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	68289-008-01	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	68289-008-20	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	68289-008-01	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	68289-008-20	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	68289-008-01	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	68289-008-20	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	68289-008-01	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	68289-008-20	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	68289-008-01	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	68289-008-20	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	68289-008-01	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	68289-008-20	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	68289-008-01	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	68289-008-20	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	68289-008-01	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	68289-008-20	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	68289-008-01	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	68289-008-20	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	68289-008-01	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	68289-008-20	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	68289-008-01	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	68289-008-20	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	68289-008-01	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	68289-008-20	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded product	product		`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	68289-008-01	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	68289-008-20	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded product	product		`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	68289-008-01	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	68289-008-20	`834df4deac94…`	`adcc014656a3…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded product	product		`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	68289-008-01	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	68289-008-20	`1332a3947898…`	`d4bfe170f9cd…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded product	product		`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	68289-008-01	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	68289-008-20	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded product	product		`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	68289-008-01	`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	68289-008-20	`86f5da6cb304…`	`a595104c45d7…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded product	product		`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	68289-008-01	`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	68289-008-20	`bd6a592717d7…`	`303034d00443…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded product	product		`8dfbde2a14a4…`	`c9ff85d89658…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded package	package	68289-008-01	`8dfbde2a14a4…`	`c9ff85d89658…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded package	package	68289-008-20	`8dfbde2a14a4…`	`c9ff85d89658…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded product	product		`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	68289-008-01	`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	68289-008-20	`e2bbac7714bc…`	`27bdfed8d636…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
A065444-001	CEPHALEXIN	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL			2009-08-28
A065444-002	CEPHALEXIN	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL			2009-08-28

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 82 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Approval date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`74a2ff9319b5…`
2022-03-09 01:35 UTC	2022-03	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`bb7c543d1eb4…`
2022-03-09 01:35 UTC	2022-03	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	A065444-001	CEPHALEXIN	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`782e0a99824c…`
2021-12-28 21:50 UTC	2021-12	A065444-002	CEPHALEXIN	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2009-08-28	`782e0a99824c…`

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
dfa3f520-409c-432e-b6d3-9250d468c772	Product name	1	20250401
64bb7f1a-2c2e-4741-8301-dbfeda7239f6	Product name	1	20190628
398aa563-bb78-fe0f-46a8-757c40ef28bf	Product name	1	20140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
68289-008-01	2019-10-21	C162847	48780-1	956f9ecf-c2d6-621f-e053-dbdaa90a74ad	Cephalexin for Oral Suspension USP
68289-008-20	2019-10-21	C162847	48780-1	956f9ecf-c2d6-621f-e053-dbdaa90a74ad	Cephalexin for Oral Suspension USP

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
68289-008-01	CephalexinUSP	100 mL in 1 BOTTLE	SUSPENSION	100		2
68289-008-20	CephalexinUSP	200 mL in 1 BOTTLE	SUSPENSION	200		2

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
CEPHALEXIN ANHYDROUS	ACTIVE INGREDIENT	5SFF1W6677	CEPHALEXIN USP (CEPHALEXIN) SUSPENSION [JAZEERA PHARMACEUTICAL]	2
CEPHALEXIN ANHYDROUS	ACTIVE MOIETY	5SFF1W6677	CEPHALEXIN USP (CEPHALEXIN) SUSPENSION [JAZEERA PHARMACEUTICAL]	2
CITRIC ACID	INACTIVE INGREDIENT	2968PHW8QP	CEPHALEXIN USP (CEPHALEXIN) SUSPENSION [JAZEERA PHARMACEUTICAL]	2
FD&C RED NO. 40	INACTIVE INGREDIENT	WZB9127XOA	CEPHALEXIN USP (CEPHALEXIN) SUSPENSION [JAZEERA PHARMACEUTICAL]	2
FD&C YELLOW NO. 6	INACTIVE INGREDIENT	H77VEI93A8	CEPHALEXIN USP (CEPHALEXIN) SUSPENSION [JAZEERA PHARMACEUTICAL]	2
SACCHARIN SODIUM	INACTIVE INGREDIENT	SB8ZUX40TY	CEPHALEXIN USP (CEPHALEXIN) SUSPENSION [JAZEERA PHARMACEUTICAL]	2
SUCROSE	INACTIVE INGREDIENT	C151H8M554	CEPHALEXIN USP (CEPHALEXIN) SUSPENSION [JAZEERA PHARMACEUTICAL]	2
XANTHAN GUM	INACTIVE INGREDIENT	TTV12P4NEE	CEPHALEXIN USP (CEPHALEXIN) SUSPENSION [JAZEERA PHARMACEUTICAL]	2

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
68289-008	CEPHALEXIN USP (CEPHALEXIN) SUSPENSION [JAZEERA PHARMACEUTICAL]	2	Legacy NDC, 2 package rows	20090922_2b388b1e-cd59-42de-ba72-858485b070b7.zip

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
5SFF1W6677	CEPHALEXIN ANHYDROUS	15686-71-2	CEPHALEXIN ANHYDROUS
OBN7UDS42Y	CEPHALEXIN	23325-78-2	Cephalexin

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
309110	cephalexin 125 MG in 5 mL Oral Suspension	PSN	2b388b1e-cd59-42de-ba72-858485b070b7	2
309113	cephalexin 250 MG in 5 mL Oral Suspension	PSN	2b388b1e-cd59-42de-ba72-858485b070b7	2
309110	cephalexin 25 MG/ML Oral Suspension	SCD	2b388b1e-cd59-42de-ba72-858485b070b7	2
309113	cephalexin 50 MG/ML Oral Suspension	SCD	2b388b1e-cd59-42de-ba72-858485b070b7	2
309110	cefalexin 25 MG/ML Oral Suspension	SY	2b388b1e-cd59-42de-ba72-858485b070b7	2
309113	cefalexin 50 MG/ML Oral Suspension	SY	2b388b1e-cd59-42de-ba72-858485b070b7	2
309110	cephalexin 125 MG per 5 ML Oral Suspension	SY	2b388b1e-cd59-42de-ba72-858485b070b7	2
309113	cephalexin 250 MG per 5 ML Oral Suspension	SY	2b388b1e-cd59-42de-ba72-858485b070b7	2

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Status
68289-008-01	68289000801	100 mL in 1 BOTTLE	100 ml	Historical
68289-008-20	68289000820	200 mL in 1 BOTTLE	200 ml	Historical

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
Cephalexin for Oral Suspension USP	Jazeera Pharmaceutical	2009-09-11	HUMAN PRESCRIPTION DRUG LABEL	2